Mike Sill, PhD
Statistician
Gynecologic Oncology Group Statistical and Data Center
Roswell Park Cancer Center
Elm and Canton St
Buffalo,
NY
USA
14263
Papers:
97 - Featured Poster
A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: a GOG study
133 - Focused Plenary
Results of Gynecologic Oncology Group (GOG) 229K: a phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma
136 - Scientific Plenary
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m
143 - Scientific Plenary
Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study
144 - Scientific Plenary
High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: a Gynecologic Oncology Group (GOG) study